Although we were unable to connect STIP1 overexpression and response to cisplatin, it was previously reported that STIP1 can be a predictor of cisplatin-resistance in bladder cancer patients, which are candidates to immunotherapy (40). This evidence concerns the gene STIP1 and urinary bladder carcinoma.